Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer.
Ezra Rosen,Manish Sharma,David Berz,Jennifer Lee Caswell-Jin,Alexander I. Spira,Georgina A. Fulgar,Mark Densel,Nawaid Rana,Samuel Sperry,Douglas Warner,Funda Meric-Bernstam
